Ovid Therapeutics Inc. reports developments as a biopharmaceutical company developing targeted small-molecule medicines for brain disorders and symptoms linked to excess neural excitability. Recurring news centers on its KCC2 direct-activator portfolio, including OV350, OV4071 and next-generation candidates, as well as OV329, a next-generation GABA-aminotransferase inhibitor being developed for treatment-resistant seizures and related rare epileptic disorders.
Company updates also cover clinical and translational data, regulatory clearances for early-stage studies, R&D events, financial results, private-placement and warrant-related capital actions, investor conference participation, and leadership or governance changes tied to the advancement of its CNS pipeline.
Ovid Therapeutics (Nasdaq: OVID) reported Q1 2026 business and financial updates, highlighting pipeline progress and strengthened capital.
OV329 showed favorable safety up to 9 mg and is moving into Phase 2 studies in treatment‑resistant epilepsies and new pediatric programs. OV4071, an oral KCC2 activator, began Phase 1 dosing. Recent PIPE financings and warrant exercises raised about $113.9 million, bringing cash and securities to $165.6 million on March 31, 2026 and extending projected runway into 2029. Q1 net loss was $17.0 million on operating expenses of $17.8 million.
Ovid Therapeutics (Nasdaq: OVID) will host a KCC2 Deep Dive R&D event on Tuesday, April 14, 2026 at 9:30 am ET in New York, with a simultaneous webcast. The session will review Ovid's first-in-class KCC2 portfolio, pharmacodynamic data, translational and clinical strategy, and market potential.
Speakers include CEO Meg Alexander, independent clinicians, translational experts, and leading neuroscientists; a webcast replay will be archived for 90 days.
Ovid Therapeutics (Nasdaq: OVID) reported new safety and PK data for OV329 (7 mg) supporting dose selection and potential best-in-category profile, announced expansion into tuberous sclerosis complex seizures and infantile spasms funded by a $60.0M private placement, and cleared OV4071 Phase 1 in Australia.
The company held $90.4M at year-end 2025, expects Phase 2 OV329 to start Q2 2026, and noted potential $53.9M from Series A warrant exercise that could extend runway into 2029.
Ovid Therapeutics (Nasdaq: OVID) announced a $60.0 million PIPE financing expected to close on or about March 19, 2026. The financing is led by Point72 and includes existing investors.
The company is selling 19,154,321 common shares at $2.01 and pre-funded warrants to purchase 10,701,710 shares at $2.009 each, with an exercise price of $0.001. Net proceeds will support expansion of OV329 into tuberous sclerosis complex and infantile spasms and general R&D; placement agents include Leerink, Oppenheimer & Co. and LifeSci Capital. Registration rights for resale were agreed with investors.
Ovid Therapeutics (Nasdaq: OVID) said management will present at three investor conferences between Feb 25 and Mar 11, 2026, with scheduled times listed for each event.
A live webcast will be available at the company’s Events & Presentations page and an archived replay will be posted for about 30 days.
Ovid Therapeutics (NASDAQ: OVID) reported Phase 1 results for OV350, the first-ever KCC2 direct activator dosed in humans. The randomized, placebo-controlled single-ascending dose study in 16 healthy participants met primary objectives for safety, tolerability, and pharmacokinetics. No treatment-related serious adverse events were reported and pharmacokinetics matched predictions. Exploratory qEEG showed central activity consistent with expected KCC2 modulation and brain exposure. The IV program will not advance further; Ovid is prioritizing oral KCC2 activators, including OV4071 (20-fold more potent than OV350) with a regulatory filing targeted in Q1 2026 and clinical start planned for Q2 2026.
Ovid Therapeutics (NASDAQ: OVID) appointed Dr. Petra Kaufmann as Chief Medical Officer effective December 2, 2025. Dr. Kaufmann will lead clinical, medical, and regulatory strategy as Ovid advances its clinical pipeline, including next-generation GABA-AT inhibitor OV329 and a portfolio of first-in-class KCC2 direct activators.
She brings experience across industry and government, including leadership roles at Vigil Neuroscience, Affinia Therapeutics, Novartis Gene Therapies and the NIH, and played a key role in development and global approvals of Zolgensma. Her background emphasizes patient-focused trial design, biomarkers, and quantitative clinical planning.
Ovid Therapeutics (NASDAQ: OVID) announced a CEO succession: Meg Alexander will become CEO effective Jan 1, 2026, with Dr. Jeremy Levin transitioning to Executive Chair. The company reported positive Phase 1 biomarker results for OV329 showing strong GABA-AT inhibition and no treatment-related ocular safety findings, and plans a Phase 2a start in Q2 2026. First-in-human data for the IV KCC2 activator OV350 is expected in Q4 2025, and the oral KCC2 activator OV4071 IND is planned for Q1 2026 with a Phase 1/1b start in Q2 2026. Financially, cash and equivalents were $25.6M as of Sept 30, 2025, augmented by an $81M initial private placement, and the company expects funding into 2H 2028. Q3 2025 results: R&D $5.9M, G&A $6.8M, total operating expenses $12.7M, net loss $12.2M ($0.17 per share).
Ovid Therapeutics (NASDAQ: OVID) announced a private placement (PIPE) expected to raise up to $175 million in gross proceeds, including initial gross proceeds of approximately $81 million, before fees and expenses. The PIPE is expected to close on or about October 6, 2025, subject to customary conditions and stockholder approvals.
The financing sells 57,722 shares of Series B preferred, Series A warrants to purchase 38,481,325 common shares and Series B warrants to purchase 28,861,000 common shares. If all preferred conversions and warrants are exercised for cash, Ovid would receive aggregate additional proceeds and issue a total of 125,064,325 common shares. The Company expects existing cash plus initial PIPE proceeds to fund operations into 2028.
Ovid (NASDAQ: OVID) announced positive topline Phase 1 results for OV329 on Oct 3, 2025. In 68 healthy volunteers (51 active; 17 placebo) OV329 5 mg produced robust biomarker evidence of GABA-AT inhibition: LICI inhibition +53% (p=0.0001) on APB and CSP prolongation +12.9 ms (FDI; p=0.00012). MRS showed mean GABA +7.13% in the medial parietal lobe at 5 mg (n=14). Safety was favorable: all treatment-related AEs were mild/transient and no ophthalmic/retinal changes observed through Day 30. Ovid plans a randomized Phase 2a in drug-resistant focal onset seizures in Q2 2026 and will complete enabling work for oral KCC2 activator OV4071 in early 2026.